o
better understand fever-specific effects in autism. In the future, Dr.
Zimmerman would like to collaborate with other research institutions to
study the underlying biologic mechanisms of fever-specific effects in
autism by conducting blood tests during and after fever and analyzing
immune measurements and hormonal changes in the blood. This research study
was the work of senior author Dr. Andrew Zimmerman of the Kennedy Krieger
Institute and the doctoral thesis of Laura Curran at Johns Hopkins
Bloomberg School of Public Health and the Kennedy Krieger Institute. The
study was funded by Cure Autism Now, which merged with the organization
Autism Speaks in 2007.
Pediatrics is an official peer-reviewed journal of the American Academy
of Pediatrics, publishing original research, clinical observations, and
special feature articles in the field of pediatrics. The journal has been
continuously published by the American Academy of Pediatrics since January
1948.
About Autism
Autism spectrum disorders (ASD) is the nation's fastest growing
developmental disorder, with current incidence rates estimated at 1 in 150
children. This year more children will be diagnosed with autism than AIDS,
diabetes and cancer combined, yet profound gaps remain in our understanding
of both the causes and cures of the disorder. Continued research and
education about developmental disruptions in individuals with ASD is
crucial, as early detection and intervention can lead to improved outcomes
in individuals with ASD.
About the Kennedy Krieger Institute
Internationally recognized for improving the lives of children and
adolescents with disorders and injuries of the brain and spinal cord, the
Kennedy Krieger Institute in Baltimore, MD serves more than 13,000
individuals each year through inpatient and outpatient clinics, home and
community services and school-based programs. Kennedy Krieger provides a
wide range of services for children with developmental conce
'/>"/>
SOURCE Kennedy Krieger Institute Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 Related medicine technology :1.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients2.
EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer3.
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain4.
Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma5.
Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor6.
Potential Safety Issue Identified in Ongoing Phase 2 Clinical Study of HCV-7967.
Study Suggests High-Dose Fish Oil May Significantly Improve Behavior in Children with ADHD8.
MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study9.
Video: Landmark Study in The Lancet: Patients Treated With Betaseron(R) After First MS Attack Experienced Significant Delay in MS Progression10.
MacroGenics Begins Global Phase 2/3 Protege Study in Recent-onset Type 1 Diabetes Mellitus11.
Sarasotas Roskamp Institute Releases Study Defining a Mechanism for Development of Obesity and the Metabolic Syndrome, Forerunners of Type 2 Diabetes